Current developments in gastric cancer: from molecular profiling to treatment strategy

被引：212

作者：

Alsina, Maria ^{[1
,2
,3
]}

Arrazubi, Virginia ^{[2
,3
]}

Diez, Marc ^{[1
,4
]}

Tabernero, Josep ^{[1
,4
]}

机构：

[1] Vall Hebron Inst Oncol VHIO, Gastrointestinal & Endocrinol Grp, Barcelona, Spain

[2] Hosp Univ Navarra HUN, Med Oncol Dept, Pamplona, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Pamplona, Spain

[4] Hosp Univ Vall Hebron HUVH, Med Oncol Dept, Barcelona, Spain

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2023年 / 20卷 / 03期

关键词：

RANDOMIZED PHASE-III; PLUS CHEMOTHERAPY CHEMO; DERUXTECAN T-DXD; GASTROESOPHAGEAL JUNCTION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; PERIOPERATIVE TRASTUZUMAB; ADENOCARCINOMA; CAPECITABINE;

D O I：

10.1038/s41575-022-00703-w

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients. Gastric and gastro-oesophageal cancer is a leading cause of cancer-related death worldwide with a poor prognosis. This Review provides a comprehensive overview of current treatment strategies set on a molecular basis, and discusses future therapeutic avenues.

引用

页码：155 / 170

页数：16

共 122 条

[21]

Cafferkey C, 2017, ANN ONCOL, V28

[22] FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC). [J].

Catenacci, Daniel V. T. ;

Kang, Yoon-Koo ;

Saeed, Anwaar ;

Yamaguchi, Kensei ;

Qin, Shukui ;

Lee, Keun-Wook ;

Kim, In-Ho ;

Oh, Sang Cheul ;

Li, Jin ;

Turk, Haci M. ;

Teixeira, Alexandra Carolina ;

Borg, Christophe ;

Hitre, Erika ;

Udrea, Anghel Adrian ;

Cardellino, Giovanni Gerardo ;

Guardeno, Raquel ;

Mitra, Siddhartha ;

Yang, Yingsi ;

Enzinger, Peter C. ;

Wainberg, Zev A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[23] Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease [J].

Catenacci, Daniel V. T. ;

Moya, Stephanie ;

Lomnicki, Samantha ;

Chase, Leah M. ;

Peterson, Bryan F. ;

Reizine, Natalie ;

Alpert, Lindsay ;

Setia, Namrata ;

Xiao, Shu-Yuan ;

Hart, John ;

Siddiqui, Uzma D. ;

Hogarth, D. Kyle ;

Eng, Oliver S. ;

Turaga, Kiran ;

Roggin, Kevin ;

Posner, Mitchell C. ;

Chang, Paul ;

Narula, Sunil ;

Rampurwala, Murtuza ;

Ji, Yuan ;

Karrison, Theodore ;

Liao, Chih-Yi ;

Polite, Blase N. ;

Kindler, Hedy L. .

CANCER DISCOVERY, 2021, 11 (02) :308-325

[24] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial [J].

Catenacci, Daniel V. T. ;

Kang, Yoon-Koo ;

Park, Haeseong ;

Uronis, Hope E. ;

Lee, Keun-Wook ;

Ng, Matthew C. H. ;

Enzinger, Peter C. ;

Park, Se Hoon ;

Gold, Philip J. ;

Lacy, Jill ;

Hochster, Howard S. ;

Oh, Sang Cheul ;

Kim, Yeul Hong ;

Marrone, Kristen A. ;

Kelly, Ronan J. ;

Juergens, Rosalyn A. ;

Kim, Jong Gwang ;

Bendell, Johanna C. ;

Alcindor, Thierry ;

Sym, Sun Jin ;

Song, Eun-Kee ;

Chee, Cheng Ean ;

Chao, Yee ;

Kim, Sunnie ;

Lockhart, A. Craig ;

Knutson, Keith L. ;

Yen, Jennifer ;

Franovic, Aleksandra ;

Nordstrom, Jeffrey L. ;

Li, Daner ;

Wigginton, Jon ;

Davidson-Moncada, Jan K. ;

Rosales, Minori Koshiji ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2020, 21 (08) :1066-1076

[25] Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma [J].

Catenacci, Daniel V. T. ;

Rasco, Drew ;

Lee, Jeeyun ;

Rha, Sun Young ;

Lee, Keun-Wook ;

Bang, Yung Jue ;

Bendell, Johanna ;

Enzinger, Peter ;

Marina, Neyssa ;

Xiang, Hong ;

Deng, Wei ;

Powers, Janine ;

Wainberg, Zev A. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) :2418-+

[26] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Catenacci, Daniel V. T. ;

Tebbutt, Niall C. ;

Davidenko, Irina ;

Murad, Andre M. ;

Al-Batran, Salah-Eddin ;

Ilson, David H. ;

Tjulandin, Sergei ;

Gotovkin, Evengy ;

Karaszewska, Boguslawa ;

Bondarenko, Igor ;

Tejani, Mohamedtaki A. ;

Udrea, Anghel A. ;

Tehfe, Mustapha ;

De Vita, Ferdinando ;

Turkington, Cheryl ;

Tang, Rui ;

Ang, Agnes ;

Zhang, Yilong ;

Hoang, Tien ;

Sidhu, Roger ;

Cunningham, David .

LANCET ONCOLOGY, 2017, 18 (11) :1467-1482

[27] Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials [J].

Chao, Joseph ;

Fuchs, Charles S. ;

Shitara, Kohei ;

Tabernero, Josep ;

Muro, Kei ;

Van Cutsem, Eric ;

Bang, Yung-Jue ;

De Vita, Ferdinando ;

Landers, Gregory ;

Yen, Chia-Jui ;

Chau, Ian ;

Elme, Anneli ;

Lee, Jeeyun ;

Ozguroglu, Mustafa ;

Catenacci, Daniel ;

Yoon, Harry H. ;

Chen, Erluo ;

Adelberg, David ;

Shih, Chie-Schin ;

Shah, Sukrut ;

Bhagia, Pooja ;

Wainberg, Zev A. .

JAMA ONCOLOGY, 2021, 7 (06) :895-902

[28] Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes [J].

Cristescu, Razvan ;

Lee, Jeeyun ;

Nebozhyn, Michael ;

Kim, Kyoung-Mee ;

Ting, Jason C. ;

Wong, Swee Seong ;

Liu, Jiangang ;

Yue, Yong Gang ;

Wang, Jian ;

Yu, Kun ;

Ye, Xiang S. ;

Do, In-Gu ;

Liu, Shawn ;

Gong, Lara ;

Fu, Jake ;

Jin, Jason Gang ;

Choi, Min Gew ;

Sohn, Tae Sung ;

Lee, Joon Ho ;

Bae, Jae Moon ;

Kim, Seung Tae ;

Park, Se Hoon ;

Sohn, Insuk ;

Jung, Sin-Ho ;

Tan, Patrick ;

Chen, Ronghua ;

Hardwick, James ;

Kang, Won Ki ;

Ayers, Mark ;

Dai Hongyue ;

Reinhard, Christoph ;

Loboda, Andrey ;

Kim, Sung ;

Aggarwal, Amit .

NATURE MEDICINE, 2015, 21 (05) :449-U217

[29] Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].

Cunningham, David ;

Starling, Naureen ;

Rao, Sheela ;

Iveson, Timothy ;

Nicolson, Marianne ;

Coxon, Fareeda ;

Middleton, Gary ;

Daniel, Francis ;

Oates, Jacqueline ;

Norman, Andrew Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46

[30] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

← 1 2 3 4 5 6 7 8 9 10 →